Peptide policy tracker

Where things stand

The July 2026 vote

The FDA Pharmacy Compounding Advisory Committee met on July 23 and 24, 2026 to discuss whether seven peptides should go on the 503A bulks list. That list names ingredients that state-licensed pharmacists and physicians may use when compounding for individual patients. The committee voted separately on each peptide in its free base and acetate forms.

Vote counts below come from two secondary reports that agree with each other. The FDA meeting page lists the agenda but does not show the vote results.

The "uses evaluated" column is what the FDA listed for each peptide on its agenda. It is not a statement that any of those uses has been shown to work.

What a yes vote does and does not mean

• It is advice to the FDA. It is not a rule, and it is not an approval of any peptide as a medicine.
• Being on the bulks list would let licensed pharmacies compound from that ingredient for an individual patient on a prescription. It would not mean the FDA has found the peptide safe or effective.
• Adding a substance to the list normally requires notice-and-comment rulemaking. The FDA says it will weigh the committee votes and public comments, and commentary notes it usually follows its advisory committees.
• Critics, including the authors of a Health Affairs commentary (opinion), argue that the evidence is thin, that the members who voted yes had ties to peptide businesses or clinics, and that product quality at compounding pharmacies is hard to assure. Supporters, including HHS Secretary Kennedy and some members of Congress, argue for easing access. The Atlas takes no side and notes both views.

Timeline

• 2023. The FDA places more than a dozen peptides, including BPC-157, in Category 2 of its interim bulks policy. Category 2 flags significant safety concerns. Source: Holland & Knight law-firm alert, October 16, 2026. Secondary source.
• February 27, 2026. HHS Secretary Robert F. Kennedy Jr. publicly backs broader peptide access. Source: Holland & Knight law-firm alert, October 16, 2026. Secondary source.
• April 15, 2026. The FDA announces it will remove 12 peptides from Category 2 after their nominations were withdrawn. This ends the safety designation but does not make them eligible for compounding. Source: Orrick, Herrington & Sutcliffe law-firm alert, April 16, 2026. Secondary source.
• May 14, 2026. The FDA bulks page, current as of this date, explains Categories 1, 2 and 3 and says the list is evaluated through rulemaking and advisory committee review. Source: U.S. Food and Drug Administration. Page content current as of May 14, 2026.
• June 29, 2026. FDA staff recommend against adding the seven peptides. The FDA announces a reconstituted advisory committee, which reports describe as having many members tied to peptide businesses or clinics. Source: Holland & Knight law-firm alert, October 16, 2026. Secondary source.
• July 23 and 24, 2026. The committee meets and votes. Six of seven peptides are recommended. Source: U.S. Food and Drug Administration meeting page. Page content current as of August 6, 2026.
• August 4, 2026. A Health Affairs commentary criticizes the vote and the committee composition. Source: Fu M, Ross JS, Nguyen NAH, Ramachandran R. Health Affairs Forefront, August 4, 2026. Opinion commentary by academic authors.
• August 24, 2026. The FDA issues five warning letters to online peptide vendors, finding that "research use only" labels did not outweigh evidence of human use, according to a law-firm review. Source: Holland & Knight law-firm alert, October 16, 2026. Secondary source.
• October 1, 2026. The FDA updates its page on unapproved GLP-1 drugs. Source: U.S. Food and Drug Administration. Page content current as of October 1, 2026. Adverse event counts are as of May 31, 2026.
• October 14, 2026. HHS sends a draft "interim access policy for compounding using certain peptides" to the White House budget office for review. Reports say it could let pharmacies compound some peptides while rulemaking is pending. It has not been issued. Source: STAT News, October 15, 2026. News report.

What is still pending

• Whether the White House clears the interim policy and the FDA issues it, and what it would cover.
• Whether the FDA accepts the committee votes and starts rulemaking.
• The second committee meeting on GHK-Cu, LL-37, Dihexa, Melanotan II and PEG-MGF.
• Possible legal challenges. A law-firm review notes that pharmaceutical trade groups have argued the FDA cannot authorize compounding through an interim policy while rulemaking is pending.
• Federal funding decisions. The FDA is funded under a temporary measure through December 11, 2026, according to the same review.

What this means for readers

• An approved medicine has been reviewed by the FDA for safety, effectiveness and quality. A compounded product has not, and a bulks-list ingredient would not change that.
• Most published research on these peptides is animal or laboratory work. The Atlas pages on the individual peptides label the evidence level.
• Rules may differ by state, by pharmacy type and by month. Ask your own clinician and pharmacist what applies to you.

Related: Compounded versus brand-name medicines | What a 503A pharmacy is | News

Questions to ask

• Is the product I am being offered an FDA-approved medicine, a compounded product, or something sold for research?
• Which pharmacy makes it, and is it licensed in my state?
• What evidence in people exists for this use?
• What happens to my plan if the rules change?

What is still unknown

• What the interim access policy says, and whether it will be issued.
• Whether the FDA will follow the committee or its own staff.
• The exact vote counts are from secondary reports. The FDA meeting page does not publish them.
• How state boards of pharmacy will respond.